Figure Legends
Figure 1A . Maculopapular rash, grade 3. The patient received
pembrolizumab for stage IV non-squamous non-small cell lung cancer.
Histopathology reveals vacuolar degeneration at the dermal-epidermal
junction, perivascular infiltration of lymphocytes and eosinophils, and
necrotic keratinocytes (hematoxylin-eosin [HE]; A2: ×10 original
magnification, A3: ×200 original magnification, A4, 5: ×400 original
magnification).
Figure 1B . Erythema multiforme, grade 2. The patient received
nivolumab for stage IV squamous non-small cell lung cancer.
Histopathology reveals vacuolar degeneration at the dermal-epidermal
junction and perivascular infiltration of lymphocytes and eosinophils,
histopathologically resembling maculopapular rash (HE; B2: ×10 original
magnification, B3: ×200 original magnification).
Figure 1C . Lichenoid reaction, grade 1. The patient received
nivolumab for metastatic melanoma. Histopathology reveals the lichenoid
infiltration of lymphocytes and a few eosinophils, and the epidermis
exhibited acanthosis, a thickened granular layer, orthokeratotic
hyperkeratosis, and spongiosis (HE; C3: ×10 original magnification, C4:
×100 original magnification).
Figure 1D . Psoriasiform reaction, grade 2. The patient received
atezolizumab for stage IV non-squamous non-small cell lung cancer.
Histopathology reveals epidermal hyperkeratotic parakeratosis and
acanthosis without a granular layer, elongation of rete ridges and
dermal papilla, mild vacuolar degeneration at the dermal-epidermal
junction, and perivascular infiltration of lymphocytes, eosinophils, and
neutrophils in the upper dermis (HE; D2: ×10 original magnification, D3:
×100 original magnification).
Figure 1E . Bullous pemphigoid, grade 1. The patient received
pembrolizumab for metastatic melanoma. Histopathology reveals
subepidermal bulla with eosinophils and perivascular infiltration of
lymphocytes and eosinophils (HE; E2: ×10 original magnification, E3:
×100 original magnification). A direct immunofluorescence test revealed
the linear deposition of IgG (E4).
Figure 1F . Scleroderma-like reaction, grade 1. The patient
received nivolumab for stage IV gastric adenocarcinoma. Histopathology
reveals increased amount of thick collagen fibers that packed sweat
glands (HE; F2: ×10 original magnification, F3: ×100 original
magnification).
Figure 1G . Stevens-Johnson syndrome, grade 3. The patient
received nivolumab for stage IV non-squamous non-small cell lung cancer.
Histopathology reveals epidermal necrosis with numerous necrotic
keratinocytes, acantholytic bullae, infiltration of lymphocytes and
eosinophils, and parakeratotic hyperkeratosis (HE; G2: ×10 original
magnification, G3: ×100 original magnification, G4: ×400 original
magnification).